Edition:
United Kingdom

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

12.46USD
23 May 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$12.46
Open
$12.68
Day's High
$12.68
Day's Low
$12.10
Volume
219,964
Avg. Vol
244,798
52-wk High
$18.65
52-wk Low
$5.14

Latest Key Developments (Source: Significant Developments)

Epizyme Q4 Loss Per Share $0.29
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Epizyme Inc ::EPIZYME PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.29.Q4 EARNINGS PER SHARE ESTIMATE $-0.47 -- REFINITIV IBES DATA.OPERATING RUNWAY INTO Q2 OF 2020.TWO SUCCESSIVE TAZEMETOSTAT NDA SUBMISSIONS FOR EPITHELIOID SARCOMA AND FOLLICULAR LYMPHOMA ON TRACK FOR 2019.EPIZYME - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $240.3 MILLION AS OF DEC 31, 2018, VERSUS $276.4 MILLION AS OF DEC 31, 2017.  Full Article

Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Epizyme Inc ::EPIZYME ANNOUNCES REGISTRATION PATH FOR TAZEMETOSTAT FOR FOLLICULAR LYMPHOMA AND PROVIDES PIPELINE UPDATES AND 2019 GUIDANCE.EPIZYME - PATH DEFINED TO SUBMIT FOR ACCELERATED APPROVAL IN ALL FL PATIENTS AFTER AT LEAST 2 PRIOR LINES OF THERAPY BASED ON FULLY ENROLLED PHASE 2 STUDY.EPIZYME INC - OPERATING RUNWAY EXTENDED INTO Q2 OF 2020.EPIZYME - RECENTLY CONDUCTED MEETING WITH FDA TO DISCUSS FL REGISTRATION STRATEGY BASED ON CURRENT PATIENT POPULATION IN ONGOING PHASE 2 CLINICAL TRIAL.EPIZYME - FOLLOWING FDA DISCUSSION, CO DEFINED REGISTRATION STRATEGY FOR TAZEMETOSTAT IN BOTH EZH2 MUTANT AND WILD TYPE FL PATIENT POPULATIONS.EPIZYME - ANTICIPATES SUBMITTING NEW DRUG APPLICATION FOR NEW INDICATION FOR TAZEMETOSTAT IN Q4 OF 2019.  Full Article

Epizyme Reports Q1 Loss Per Share Of $0.49
Tuesday, 8 May 2018 

May 8 (Reuters) - Epizyme Inc ::EPIZYME REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q1 LOSS PER SHARE $0.49.Q1 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.EPIZYME - CONTINUES TO EXPECT EXISTING CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF MARCH 31 TO BE SUFFICIENT TO FUND OPERATIONS INTO Q3 2019.  Full Article

Epizyme Q4 Loss Per Share $0.52
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Epizyme Inc ::EPIZYME REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND 2018 MILESTONES.Q4 LOSS PER SHARE $0.52.Q4 EARNINGS PER SHARE VIEW $-0.57 -- THOMSON REUTERS I/B/E/S.EPIZYME - SEES EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DEC 31, 2017 TO BE SUFFICIENT TO FUND OPERATIONS INTO Q3 2019.  Full Article

Epizyme says ‍no revenue recognized in Q3 of 2017 compared to $6.6 mln for Q3 of 2016​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Epizyme Inc :Epizyme reports third quarter 2017 operating results and company updates.Epizyme Inc - ‍no revenue recognized in q3 of 2017, compared to $6.6 million for q3 of 2016​.Epizyme Inc - ‍research and development (research and development) expenses were $28.7 million for q3 of 2017, compared to $23.9 million​.Epizyme Inc - ‍existing cash, cash equivalents and marketable securities as of sept 30 will be sufficient to fund planned operations into at least q3 2019​.  Full Article

Epizyme announces pricing of public offering of common stock
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - Epizyme Inc ::Epizyme announces pricing of public offering of common stock.Says public offering of 9.18 million common shares priced at $15.25per share.  Full Article

Epizyme announces proposed public offering of common stock
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - Epizyme Inc :Epizyme announces proposed public offering of common stock.Epizyme Inc says ‍intends to offer and sell $120 million of shares of its common stock in an underwritten public offering​.Epizyme-Will use ‍net proceeds from this offering,existing cash, cash equivalents,marketable securities,to fund development costs of tazemetostat outside Japan​.  Full Article

Epizyme says CFO ‍Andrew E. Singer will be leaving co at end of August​
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - Epizyme Inc :Epizyme announces leadership transition for finance organization.‍Andrew E. Singer, chief financial officer of Epizyme, will be leaving company at end of august​.Epizyme Inc - as part of transition, Susan Graf, chief business officer of Epizyme, will assume responsibility for finance organization going forward,.  Full Article

Epizyme reports Q2 loss of $0.48/shr
Friday, 4 Aug 2017 

Aug 4 (Reuters) - Epizyme Inc :Epizyme reports second quarter 2017 financial results and clinical and business progress.Epizyme Inc qtrly loss per share $0.48.Q2 revenue $10 million.Q2 revenue view $2.8 million -- Thomson Reuters I/B/E/S.  Full Article

Epizyme expands clinical collaboration with Genentech
Monday, 26 Jun 2017 

June 26 (Reuters) - Epizyme Inc :Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc.Epizyme inc - expanded its clinical collaboration with genentech, a member of roche group.Epizyme inc - under new agreement, tazemetostat administered in combination with atezolizumab will be evaluated in a phase 1b/2 clinical study.Epizyme inc - financial terms are not disclosed and epizyme will retain global development and commercialization rights to tazemetostat..Epizyme inc - genentech will sponsor planned phase 1b/2 clinical trial, which is expected to be initiated by end of 2017.  Full Article